Apoptosis of peripheral blood mononuclear cells in Kawasaki disease

Journal of Rheumatology

Volumn 27, Issue 3, 2000, Pages 801-806

  Kim, Hyun Young ^a,b   Lee, Hong Gyu ^a,c   Kim, Dong Soo ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Bundang Jesaeng Hospital   (South Korea)

^c Department of Pediatrics   (South Korea)

Author keywords

Apoptosis; Fas Fas ligand; Kawasaki disease; Soluble Fas

Indexed keywords

FAS ANTIGEN;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; MUCOCUTANEOUS LYMPH NODE SYNDROME; PATHOGENESIS; PRESCHOOL CHILD; PRIORITY JOURNAL;

ACUTE DISEASE; ANTIGENS, CD95; APOPTOSIS; B-LYMPHOCYTES; CHILD, PRESCHOOL; DNA FRAGMENTATION; FAS LIGAND PROTEIN; FEVER; HUMANS; LEUKOCYTE COUNT; MEMBRANE GLYCOPROTEINS; MONOCYTES; MUCOCUTANEOUS LYMPH NODE SYNDROME; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; TIME FACTORS;

EID: 0342545963     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Kawasaki T. Acute febrile monocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children: clinical observations of 50 cases. Jpn J Allerg 1967;16:178-222.
2. Shulman ST, De Inocencio J, Hirsh R. Kawasaki disease. Pediatr Clin N Am 1995;42:1205-22.
3. Leung DYM, Meissner HC, Fulton DR, Murray DL, Kotzin BL, Schielvert PM. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1993;32:1385-8.
4. Terai M, Miwa K, Williams T, et al. The absence of evidence of staphylococcal toxin involvement in the pathogenesis of Kawasaki disease. J Infect Dis 1995;172:558-61.
5. Leung KYM, Collins T, Lapierre LA, Geha RS, Pober JS. IgM antibodies present in the acute phase of Kawasaki syndrome lyse cultured vascular endothelial cells stimulated by gamma interferon. J Clin Invest 1986;77:1428-35.
6. Guzman J, Fung M, Petty RE. Diagnostic value of anti-neutrophil cytoplasmic and anti-endothelial cell antibodies in early Kawasaki disease. J Pediatr 1994;124:917-20.
7. Kobayashi S, Wada N, Kubo M. Antibodies to native type III collagen in the serum of patients with Kawasaki disease. Eur J Pediatr 1992;151:183-7.
8. Leung KYM, Cotran RS, Kurt-Jones E, Burns JC, Newsburger JW, Pober JS. Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 1989;2:1298-302.
9. Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin-2 receptor, and interferon-gamma in Kawasaki disease involved coronary artery lesions. Clin Immunol Immunopathol 1990;56:29-36.
10. Kim DS. Serum interleukin-6 in Kawasaki disease. Yonsei Med J 1992;33:183-8.
11. Kim DS, Lee HK, Noh GW, Lee SI, Lee KY. Increased serum interleukin 10 level in Kawasaki disease. Yonsei Med J 1996;37:125-30.
12. Choi IH, Chwae YJ, Shim WS, et al. Clonal expansion of CD8+ T cells in Kawasaki disease. J Immunol 1997;159:481-6.
13. Lang BA, Silverman ED, Laxer RM, Rose V, Nelson DL, Rubin LA. Serum soluble interleukin-2 receptor levels in Kawasaki disease. J Pediatr 1990;116:592-6.
14. Kim GJ, Kim DS. The soluble interleukin 2 levels in Kawasaki disease. J Korean Pediatr Soc 1992;35:1657-66.
15. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
16. Leung KYM. Immunomodulation by intravenous immune globulin in Kawasaki disease. J Allergy Clin Immunol 1989;84:588-94.
17. Abe J, Kotzin BL, Jujo K, et al. Selective expansion of T cells expressing TCR variable regions V beta 2 and V beta 8 in Kawasaki disease. Proc Natl Acad Sci USA 1992;89:4066-70.
18. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function and clinical application. Ann Intern Med 1990;113:619-27.
19. Leung KYM, Giorno RC, Kazemi LV, Flynn PA, Busse JB. Evidence for superantigen involvement in cardiovascular injury due to Kawasaki syndrome. J Immunol 1995;155:5019-21.
20. Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-43.
21. Lynch DH, Watson ML, Alderson MR, et al. The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity 1994;1:131-6.
22. Takahashi T, Tanaka M, Brennan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994;76:969-76.
23. Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1992;263:1759-62.
24. Piazza C, Montani MSG, Moretti S, Cundari E, Poccolella E. CD4+ T cells kill CD8+ T cells via Fas/Fas ligand mediated apoptosis. J Immunol 1997;158:1503-6.
25. Rose LM, Latchman DS, Isenberg DA. Elevated soluble Fas production in SLE correlates with HLA status not with disease activity. Lupus 1997;6:717-22.
26. Jodo S, Kobayashi S, Kayagaki N, et al. Serum levels of soluble Fas/APO-1(CD95) and its molecular structure in patients with systemic lupus erythematosus and other autoimmune disease. Clin Exp Immunol 1997;107:89-95.
27. Nozowa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hashimoto H. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic disease. Arthritis Rheum 1997;40:1126-9.